IP Library › Granted Patent US 8,816,088
Granted Patent B2
US 8,816,088 · App. 13/964,484 · Granted Aug 26, 2014

Diamide compounds having muscarinic receptor antagonist and β

Inventors: Adam D. Hughes (Belmont, CA); Yan Chen (Foster City, CA); John R. Jacobsen (San Mateo, CA); Eric L. Stangeland (Pacifica, CA); Rose Yen (San Francisco, CA)
Assignee: Theravance Respiratory Company, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,816,088
App. No.
13/964,484
Granted
Aug 26, 2014
Kind
B2
Abstract

This invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and β 2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.

Claims (1)

1. Biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}phenylcarbamoyl)-butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester of the formula:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2020
From: THERAVANCE RESPIRATORY COMPANY, LLC
To: THERAVANCE BIOPHARMA R&D IP, LLC
Reel/Frame 054393/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2014
From: THERAVANCE, INC.
To: THERAVANCE RESPIRATORY COMPANY, LLC
Reel/Frame 033175/0547 →
Continuity (4)
Continuation 13369109 · Feb 8, 2012
Division 12761532 · Apr 16, 2010
Provisional Application 61172039 · Apr 23, 2009
Related Publication 20130331364A1 · Dec 12, 2013